Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Andrey A, Gorchakov"'
Autor:
Maria G. Byazrova, Ekaterina A. Astakhova, Aygul R. Minnegalieva, Maria M. Sukhova, Artem A. Mikhailov, Alexey G. Prilipov, Andrey A. Gorchakov, Alexander V. Filatov
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Replication-incompetent adenoviral vectors have been extensively used as a platform for vaccine design, with at least four anti-COVID-19 vaccines authorized to date. These vaccines elicit neutralizing antibody responses directed against SARS
Externí odkaz:
https://doaj.org/article/c130c6f0fcc84237b064628771f0d130
Autor:
Pavel P. Solodkov, Alexander M. Najakshin, Nikolai A. Chikaev, Sergey V. Kulemzin, Ludmila V. Mechetina, Konstantin O. Baranov, Sergey V. Guselnikov, Andrey A. Gorchakov, Tatyana N. Belovezhets, Anton N. Chikaev, Olga Y. Volkova, Alexander G. Markhaev, Yulia V. Kononova, Alexander Y. Alekseev, Marina A. Gulyaeva, Alexander M. Shestopalov, Alexander V. Taranin
Publikováno v:
Vaccines, Vol 12, Iss 2, p 129 (2024)
The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majo
Externí odkaz:
https://doaj.org/article/3f932639df4445969276ce69457f349c
Autor:
Sergey V. Kulemzin, Sergey V. Guselnikov, Boris G. Nekrasov, Svetlana V. Molodykh, Irina N. Kuvshinova, Svetlana V. Murasheva, Tatyana N. Belovezhets, Andrey A. Gorchakov, Anton N. Chikaev, Nikolai A. Chikaev, Olga Y. Volkova, Anna A. Yurina, Alexander M. Najakshin, Alexander V. Taranin
Publikováno v:
Vaccines, Vol 12, Iss 1, p 55 (2024)
SARS-CoV-2 has a relatively high mutation rate, with the frequent emergence of new variants of concern (VOCs). Each subsequent variant is more difficult to neutralize by the sera of vaccinated individuals and convalescents. Some decrease in neutraliz
Externí odkaz:
https://doaj.org/article/aad5822efb674e47a6cbbe12f6831599
Autor:
Andrey A. Gorchakov, Sergey V. Kulemzin, Sergey V. Guselnikov, Konstantin O. Baranov, Tatyana N. Belovezhets, Ludmila V. Mechetina, Olga Yu. Volkova, Alexander M. Najakshin, Nikolai A. Chikaev, Anton N. Chikaev, Pavel P. Solodkov, Victor F. Larichev, Marina A. Gulyaeva, Alexander G. Markhaev, Yulia V. Kononova, Alexander Yu. Alekseyev, Alexander M. Shestopalov, Gaukhar M. Yusubalieva, Tatiana V. Klypa, Alexander V. Ivanov, Vladimir T. Valuev-Elliston, Vladimir P. Baklaushev, Alexander V. Taranin
Publikováno v:
Cell Discovery, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract In the absence of virus-targeting small-molecule drugs approved for the treatment and prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing antibodies represents an important area of research in response to the
Externí odkaz:
https://doaj.org/article/934387379f904a258f5fe50970741e70
Autor:
Maria G. Byazrova, Sergey V. Kulemzin, Ekaterina A. Astakhova, Tatyana N. Belovezhets, Grigory A. Efimov, Anton N. Chikaev, Ilya O. Kolotygin, Andrey A. Gorchakov, Alexander V. Taranin, Alexander V. Filatov
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The development of effective vaccines against SARS-CoV-2 remains a global health priority. Despite extensive use, the effects of Sputnik V on B cell immunity need to be explored in detail. We performed comprehensive profiling of humoral and B cell re
Externí odkaz:
https://doaj.org/article/158ab0e960dd46d9ae4dd4d9e4fff3e3
Autor:
Sergey V Guselnikov, Tatyana N Belovezhets, Sergey V Kulemzin, Andrey A Gorchakov, Alexander V Taranin
Publikováno v:
BioTechniques, Vol 67, Iss 4, Pp 184-187 (2019)
Cloning VH and VL genes from individual antigen-specific B cells is an attractive approach for producing monoclonal antibodies of the desired specificity. Current RT-PCR protocols, however, result in the successful identification of VH and VL gene pa
Externí odkaz:
https://doaj.org/article/56d4dfdee4f743cb9a777b95dc095966
Autor:
Sergey V. Kulemzin, Daria A. Matvienko, Artur H. Sabirov, Arpine M. Sokratyan, Daria S. Chernikova, Tatyana N. Belovezhets, Anton N. Chikaev, Aleksandr V. Taranin, Andrey A. Gorchakov
Publikováno v:
BMC Medical Genomics, Vol 12, Iss S2, Pp 87-95 (2019)
Abstract Background Cytotoxic activity of T- and NK-cells can be efficiently retargeted against cancer cells using chimeric antigen receptors (CARs) and rTCRs. In the context of solid cancers, use of armored CAR T- and NK cells secreting additional a
Externí odkaz:
https://doaj.org/article/34e7d0d2590c4b39a88edf99523c4e5b
Autor:
Ekaterina A. Astakhova, Maria G. Byazrova, Gaukhar M. Yusubalieva, Sergey V. Kulemzin, Natalia A. Kruglova, Alexey G. Prilipov, Vladimir P. Baklaushev, Andrey A. Gorchakov, Alexander V. Taranin, Alexander V. Filatov
Publikováno v:
Cells, Vol 11, Iss 13, p 1991 (2022)
Both SARS-CoV-2 infection and vaccination have previously been demonstrated to elicit robust, yet somewhat limited immunity against the evolving variants of SARS-CoV-2. Nevertheless, reports performing side-by-side comparison of immune responses foll
Externí odkaz:
https://doaj.org/article/21eee7f5cd5547fdb89d07dfe90d8652
Autor:
Ekaterina A Astakhova, Alexey A Morozov, Maria G Byazrova, Maria M Sukhova, Artem A Mikhailov, Andrey A Gorchakov, Alexander V Filatov
Rapid emergence of evasive SARS-CoV-2 variants is an on-going challenge for COVID-19 vaccinology. Traditional virus neutralization tests provide detailed datasets of neutralization titers against the viral variants. Such datasets are difficult to int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d0bbedc567ee735c411892fa450ec7b
https://doi.org/10.20944/preprints202305.1591.v1
https://doi.org/10.20944/preprints202305.1591.v1
Autor:
Sergey V. Kulemzin, Maria V. Sergeeva, Konstantin O. Baranov, Andrey A. Gorchakov, Sergey V. Guselnikov, Tatyana N. Belovezhets, Olga Yu. Volkova, Alexander M. Najakshin, Nikolai A. Chikaev, Daria M. Danilenko, Alexander V. Taranin
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 6; Pages: 895
Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f780e836ec21c1ca2477f0db4f0f02e1